U.S. patent application number 09/735504 was filed with the patent office on 2001-12-20 for non-steroidal ligands for the estrogen receptor.
This patent application is currently assigned to GLAXO WELLCOME INC... Invention is credited to Willson, Timothy Mark.
Application Number | 20010053774 09/735504 |
Document ID | / |
Family ID | 26792695 |
Filed Date | 2001-12-20 |
United States Patent
Application |
20010053774 |
Kind Code |
A1 |
Willson, Timothy Mark |
December 20, 2001 |
Non-steroidal ligands for the estrogen receptor
Abstract
Novel non-steroidal ligands for the estrogen receptor which
possess tissue-dependent estrogenic and antiestrogenic activity as
well as methods for making the same and their applications in
treating a variety of disease states.
Inventors: |
Willson, Timothy Mark;
(Durham, NC) |
Correspondence
Address: |
Nixon & Vanderhye P.C.
8th Floor
1100 N. Glebe Rd.
Arlington
VA
22201
US
|
Assignee: |
GLAXO WELLCOME INC..
|
Family ID: |
26792695 |
Appl. No.: |
09/735504 |
Filed: |
December 14, 2000 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09735504 |
Dec 14, 2000 |
|
|
|
09182244 |
Oct 30, 1998 |
|
|
|
6207716 |
|
|
|
|
09182244 |
Oct 30, 1998 |
|
|
|
08877665 |
Jun 18, 1997 |
|
|
|
5877219 |
|
|
|
|
08877665 |
Jun 18, 1997 |
|
|
|
08232910 |
Apr 25, 1994 |
|
|
|
5681835 |
|
|
|
|
Current U.S.
Class: |
514/125 ;
514/374; 514/378; 514/521; 514/602; 548/235; 548/240; 558/166;
558/413; 564/171; 564/84 |
Current CPC
Class: |
C07C 2601/02 20170501;
C07C 57/48 20130101; C07C 33/28 20130101; C07D 271/06 20130101;
C07C 251/40 20130101; C07C 211/28 20130101; A61P 35/00 20180101;
C07C 233/40 20130101; C07C 255/34 20130101; C07C 233/58 20130101;
C07C 2601/14 20170501; C07C 57/42 20130101; C07C 233/11 20130101;
C07C 45/45 20130101; C07B 2200/07 20130101; C07C 327/48 20130101;
C07F 9/4006 20130101; C07C 47/548 20130101; C07D 295/185 20130101;
A61P 9/00 20180101; C07C 233/22 20130101; C07C 327/44 20130101;
A61P 19/02 20180101; A61P 19/00 20180101; A61P 19/10 20180101; C07C
49/796 20130101; C07C 69/618 20130101; A61K 31/135 20130101; C07C
45/59 20130101; A61K 31/165 20130101; C07C 45/45 20130101; C07C
47/548 20130101; C07C 45/59 20130101; C07C 49/796 20130101 |
Class at
Publication: |
514/125 ;
514/374; 514/378; 514/521; 514/602; 558/166; 558/413; 564/84;
564/171; 548/235; 548/240 |
International
Class: |
A61K 031/66; A61K
031/42; A61K 031/277; A61K 031/18; A61K 031/165 |
Claims
We claim:
1. A compound of Formula I: 12wherein R.sup.1 is
--(CH.sub.2).sub.nCR.sup- .5.dbd.CR.sup.6R.sup.7;
--(CH.sub.2).sub.mC(X)NR.sup.8R.sup.9; or 13R.sup.2 and R.sup.3 are
independently H, --CH.sub.3, --OH, --OCH3, --OCH.sub.2CH.sub.3 or
--CH.sub.2(CH.sub.3).sub.2; R.sup.4 is --CN, --NO.sub.2,
--CH.sub.3, --CH.sub.2CH.sub.3, --CH.sub.2CH.sub.2--Y or --Y;
R.sup.5and R.sup.6 are independently H, --C.sub.1-4alkyl,
--C.sub.2-4alkenyl, --C.sub.2-4alkynyl, --X--C.sub.1-3alkyl,
--X--C.sub.2-4alkenyl, --X--C.sub.2-4alkynyl or --Y; R.sup.7 is
--CN, --C.sub.1-4alkyl--OH, --C(O)O(CH.sub.3).sub.3 ,
--C(O)NR.sup.10R.sup.11, --C(O)NR.sup.12R.sup.13,
--C.sub.1-4alkyl--NR.sup.10R.sup.11 , --C(O)R.sup.12,
--C(O)OR.sup.12, --C(O)NR.sup.12OR.sup.13, --C(O)NHC(O)R.sup.12,
--C(O)NHCH.sub.2R.sup.12, --C(NH.sub.2)(NOR.sup.12 ),
--S(O)R.sup.12, --S(O)(O)(OR.sup.12),
--S(O)(O)(NHCO.sub.2R.sup.12), PO.sub.3R.sup.12,
--P(O)(NR.sup.12R.sup.13)(NR.sup.12R.sup.13),
--P(O)(NR.sup.12R.sup.13)(OR.sup.14),
--CONR.sup.12(CH.sub.2).sub.qOCH.su- b.3,
--CONR.sup.12(CH.sub.2).sub.qNR.sup.8R.sup.9 or oxadizole
substituted with methyl; R.sup.8 and R.sup.9 are independently
hydrogen, --C.sub.1-7alkyl, --C.sub.3-7cycloalkyl,
--O--C.sub.1-7alkyl, --C.sub.1-7alkyl--Y or phenyl; R.sup.10 and
R.sup.11 are independently methyl or ethyl or, taken together form
a morpholino group bonded via its nitrogen atom; R.sup.12, R.sup.13
and R.sup.14 are independently H, --C.sub.1-12alkyl,
--C.sub.2-12alkenyl, --C.sub.2-12alkynyl, --O--C.sub.1-12alkyl,
--O--C.sub.2-12-alkenyl, --O--C.sub.2-12alkynyl,
--C.sub.3-7cycloalkyl, --C.sub.3-7cycloalkenyl, linear and cyclic
heteroalkyl, aryl, heteroaryl or --Y; X is oxygen or sulfur; Y is a
halogen; n is an integer selected from 0, 1 or 2; m is the integer
1 or 2; p is an integer selected from 1 to 4; and q is an integer
from 1-12.
2. A compound according to claim 1 wherein X is 0.
3. A compound according to claim 2 wherein R.sup.1 is R.sup.1 is
--(CH.sub.2).sub.nCR.sup.5.dbd.CR.sub.6R.sup.7.
4. A compound according to claim 1 wherein R.sup.2 and R.sup.3 are
independently selected from H, --OH or --OCH.sub.3.
5. A compound according to claim 4 wherein R.sup.2 and R.sup.3 are
H.
6. A compound according to claim 1 wherein R.sup.4 is either
--CH.sub.3, --CH.sub.2CH.sub.3 or --CH.sub.2CH.sub.2--Cl.
7. A compound according to claim 1 wherein R.sup.5 and R.sup.6 are
independently H or --C.sub.1-4alkyl.
8. A compound according to claim 1 wherein R.sup.8 and R.sup.9 are
independently hydrogen, --C.sub.1-7alkyl or
--C.sub.3-7cycloalkyl.
9. A compound according to claim 3 wherein R.sup.7 is
C(O)O(CH.sub.3).sub.3 --C(O)NR.sup.10R.sup.11,
--C(O)NR.sup.12R.sup.13, --C(O)OR.sup.12, --C(O)NHC(O)R.sup.12,
--C(NH.sub.2)(NOR.sup.12), --S(O)(O)(NHCO.sub.2R.sup.12),
PO.sub.3R.sup.12, --P(O)(NR.sup.12R.sup.13- )(NR.sup.12R.sup.13) or
P(O)(NR.sup.12R.sup.13)(OR.sup.14).
10. A compound according to claim 1 wherein R.sup.12, R.sup.13 and
R.sup.14 are independently H, --C.sub.1-12alkyl,
--C.sub.2-12alkenyl.
11. A compound according to claim 1 wherein the compound is
selected from one of the following:
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl acrylamide;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl propionamide;
2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]cyclopropanecarboxyli- c acid
diethylamide;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl-2--
methyl-acrylamide;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-but-2-enoic acid
diethylamide; 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid
methyl ester; 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylonitrile;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid tert-butyl
ester; 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-1-morpholin-4-yl-prop-2-en-1-one;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-(3-methoxy-propyl)-acrylamide;
-N,N-Dicyclohexyl-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]acrylamide;
-N-(2-Dimethylamino-ethyl)-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-N-ethyl
acrylamide; 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-methyl-N-octyl
acrylamide; 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]acrylamide;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-ethyl acrylamide;
1-Amino-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-prop-2-ene-1-one
oxime;
3-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-5-methyl-[1,2,4]-oxadiaz-
ole; 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-prop-2-ene-1-ol;
{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-allyl}-dimethylamine;
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl thioacrylamide;
or
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-(3-hydroxy-propyl)-acrylamide.
12. A method of treating a mammal for osteoporosis comprising
administering to said mammal an effective amount of a compound
according to claim 1.
13. A method of treating a mammal for arthritic diseases which
comprises administering to said mammal an effective amount of a
compound according to claim 1.
14. A method of treating a mammal for breast cancer which comprises
administering to said mammal an effective amount of a compound
according to claim 1.
15. A method of treating a mammal for cardiovascular disease which
comprises administering to said mammal an effective amount of a
compound according to claim 1.
16. A method of preventing osteoporosis in a mammal comprising
administering to said mammal an effective amount of a compound
according to claim 1.
17. A method of preventing arthritic diseases in a mammal which
comprises administering to said mammal an effective amount of a
compound according to claim 1.
18. A method of preventing breast cancer in a mammal which
comprises administering to said mammal an effective amount of a
compound according to claim 1.
19. A method of preventing cardiovascular disease in a mammal which
comprises administering to said mammal an effective amount of a
compound according to claim 1.
Description
FIELD OF INVENTION
[0001] The present invention relates to novel non-steroidal ligands
for the estrogen receptor which possess tissue-dependent estrogenic
and antiestrogenic activity as well as methods for making the same
and their applications in treating a variety of disease states.
BACKGROUND OF THE INVENTION
[0002] Estrogens are an important class of steroidal hormones that
stimulate the development and maintenance of fundamental sexual
characteristics in humans. In the past, estrogens have been found
useful in the treatment of certain medical conditions and diseases.
For example, estradiol, a steroid hormone produced by the ovary, is
useful in the treatment of osteoporosis, cardiovascular disease,
premenstrual syndrome, vasomotor symptoms associated with
menopause, atrophic vagginitis, Kraurosis vulvae, female
hypogonadism, primary ovarian failure, excessive hair growth and
prostatic cancer. Unfortunately, administration of such steroids
have been associated with a number of side effects, including
myocardial infarction, thromboembolism, cerebrovascular disease,
and endometrial carcinoma.
[0003] For example, hormone replacement therapy (HRT) with estrogen
has been determined to be a clinically effective treatment for
osteoporosis in post-menopausal women, however less than 15% of
eligible women are currently prescribed HRT despite clinical trials
that have demonstrated a 50% reduction in hip fractures and a 30%
reduction in cardiovascular disease. Non-compliance arises from
patient and physician concerns over the two fold increased risk of
endometrial cancer observed with HRT employing estrogen alone as
well as the association between estrogen therapy and breast cancer.
Although unproven in the clinic, this suspected risk for breast
cancer has led to HRT being contra-indicated in a significant
percentage of post-menopausal women. Co-therapy with progestins has
been shown to protect the uterus against cancer while maintaining
the osteoprotective effects of the estrogen, however the progestin
introduces other side-effects such as withdrawal bleeding, breast
pain and mood swings.
[0004] In light of problems associated with estrogen therapy, a
significant amount of research has been carried out to identify
effective nonsteroidal estrogen and antiestrogenic compounds. In
general, such compounds may be characterized as both estrogenic and
antiestrogenic because while they all bind to the estrogen
receptor, they may induce an estrogenic or antiestrogenic effect
depending upon the location of the receptor. In the past, it has
been postulated that the binding of various nonsteroidal estrogen
and antiestrogenic compounds to the estrogen receptor was due to
the presence of a common pharmacophore (shown below in Scheme A)
which was recurrent in the chemical structures of these compounds.
1
[0005] This pharmacophore later became the structural backbone
around which nonsteroidal estrogen and antiestrogenic compounds
were constructed. Its presence in the constructs of various
compounds such as hexestrol, tamoxifen, chroman, triphenylethylene,
DES, clomiphene, centchroman, nafoxidene, trioxifene, toremifene,
zindoxifene, raloxifene, droloxifene, DABP, TAT-59 and other
structurally related compounds has become accepted in the art as
the molecular key to estrogen receptor binding specificity.
[0006] An example of one noteworthy nonsteroidal antiestrogen is
tamoxifen (TAM),
(Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene,
which is a triphenyl ethylene derivative. Tamoxifen effectively
antagonizes the growth-promoting effect of estrogens in primary
target tissues such as the breast and ovum.
[0007] Currently, this non-steroidal estrogen as well as a
structurally similar compound known as raloxifene have been
developed for the treatment and/or prevention of osteoporosis,
cardiovascular disease and breast cancer in addition to the
treatment and/or prevention of a variety of other disease states.
Both compounds have been shown to exhibit an osteoprotective effect
on bone mineral density combined with a positive effect on plasma
cholesterol levels and a greatly reduced incidence of breast and
uterine cancer. Unfortunately, tamoxifen and raloxifene both have
unacceptable levels of life-threatening side effects such as
endometrial cancer and hepatocellular carcinoma.
[0008] Accordingly, it would be advantageous to develop a series of
non-steroidal compounds which retain beneficial characteristics
such as osteoprotective activity while minimizing any undesirable
side effects. While it is presently accepted that the pharmacophore
backbone mentioned above is responsible for estrogen receptor
binding specificity, it has now been discovered that certain novel
estrogen binding ligands can be constructed as set forth herein
which incorporate particular moieties onto such pharmacophore-based
compounds, thereby maximizing beneficial characteristics such as
osteoprotective function while minimizing undesireable
characteristics such as an increased risk of cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 sets forth data representative of the uterotrophic
activity of the compounds of the present invention in immature
rats.
[0010] FIG. 2 sets forth data representative of changes in bone
mineral density in ovariectomized rats in lumbar spine and
tibia.
SUMMARY OF THE INVENTION
[0011] The present invention comprises the genus of compounds
represented by Formula (I) 2
FORMULA I
[0012] wherein R.sup.1-R.sup.4 are defined hereinafter. Also part
of the present invention are pharmaceutical compositions comprising
one or more of the compounds of Formula (I) as well as their use,
methods for their preparation and intermediates involved in the
synthesis of the same.
DETAILED DESCRIPTION OF THE INVENTION
[0013] The present invention comprises the genus of compounds
represented by Formula (I): 3
[0014] wherein
[0015] R.sup.1 is --(CH.sub.2).sub.nCR.sup.5.dbd.CR.sup.6R.sup.7;
--(CH.sub.2).sub.mC(X)NR.sup.8R.sup.9; or 4
[0016] R.sup.2 and R.sup.3 are independently H, --CH.sub.3, --OH,
--OCH3, --OCH.sub.2CH.sub.3 or --CH.sub.2(CH.sub.3).sub.2;
[0017] R.sup.4 is --CN, --NO.sub.2, --CH.sub.3, --CH.sub.2CH.sub.3,
--CH.sub.2CH.sub.2--Y or --Y;
[0018] R.sup.5and R.sup.6 are independently H, --C.sub.1-4alkyl,
--C.sub.2-4alkenyl, --C.sub.2-4alkynyl, --X--C.sub.1-3alkyl,
--X--C.sub.2-4alkenyl, --X--C.sub.2-4alkynyl or --Y;
[0019] R.sup.7 is --CN, --C.sub.1-4alkyl--OH,
--C(O)O(CH.sub.3).sub.3 , --C(O)NR.sup.10R.sup.11,
--C(O)NR.sup.12R.sup.13, --C.sub.1-4alkyl--NR.su- p.10R.sup.11 ,
--C(O)R.sup.12, --C(O)OR.sup.12, --C(O)NR.sup.12OR.sup.13,
--C(O)NHC(O)R.sup.12, --C(O)NHCH.sub.2R.sup.12,
--C(NH.sub.2)(NOR.sup.12 ), --S(O)R.sup.12, --S(O)(O)(OR.sup.12),
--S(O)(O)(NHCO.sub.2R.sup.12), PO.sub.3R.sup.12,
--P(O)(NR.sup.12R.sup.13)(NR.sup.12R.sup.13),
--P(O)(NR.sup.12R.sup.13)(OR.sup.14),
--CONR.sup.12(CH.sub.2).sub.qOCH.su- b.3,
--CONR.sup.12(CH.sub.2).sub.qNR.sup.8R.sup.9 or oxadizole
substituted with methyl;
[0020] R.sup.8 and R.sup.9 are independently hydrogen,
--C.sub.1-7alkyl, --C.sub.3-7cycloalkyl, --O--C.sub.1-7alkyl,
--C.sub.1-7alkyl--Y or phenyl;
[0021] R.sup.10 and R.sup.11 are independently methyl or ethyl or,
taken together form a morpholino group bonded via its nitrogen
atom;
[0022] R.sup.12, R.sup.13 and R.sup.14 are independently H,
--C.sub.1-12alkyl, --C.sub.2-12alkenyl, --C.sub.2-12alkynyl,
--O--C.sub.1-12alkyl, --O--C.sub.2-12-alkenyl,
--O--C.sub.2-12alkynyl, --C.sub.3-7cycloalkyl,
--C.sub.3-7cycloalkenyl, linear and cyclic heteroalkyl, aryl,
heteroaryl or --Y;
[0023] X is oxygen or sulfur;
[0024] Y is a halogen;
[0025] n is an integer selected from 0, 1 or 2;
[0026] m is the integer 1 or 2;
[0027] p is an integer selected from 1 to 4; and
[0028] q is an integer from 1-12.
[0029] As provided herein, the term "alkyl", alone or in
combination, is defined herein to be straight chain or branched
chain saturated hydrocarbon groups from C.sub.1 to C.sub.7 unless
otherwise preceeded by some other chain length designator. The term
"lower alkyl" is defined herein as C.sub.1 to C.sub.4 unless
otherwise preceeded by some other chain length designator.
Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl,
isobutyl, n-butyl, n-hexyl, and the like.
[0030] The term "haloalkyl" is defined herein as an alkyl
substituted with one or more halogens. The term "cycloalkyl" is
defined herein to include cyclic hydrocarbon radicals from
C.sub.3-C.sub.7. Some exemplary cycloalkyl radicals include
cyclopropyl, cyclobutyl, cyclobutyl, and cyclopentyl.
[0031] The term "aryl", alone or in combination, is defined herein
as a monocyclic or polycyclic group, preferably a monocyclic or
bicyclic group, i.e. phenyl or naphthyl, which can be unsubstituted
or substituted, for example, with one or more and, in particular,
one to three substituents selected from halogen, alkyl, hydroxy,
alkoxy, haloalkyl, nitro, amino, acylamino, alkylthio,
alkylsulfinyl and alkylsulfonyl. Some exemplary aryl groups include
phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,
2-methylphenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl,
4-nitrophenyl, and the like.
[0032] The term "heteroaryl" is defined herein as a 5-membered or
6-membered heterocyclic aromatic group which can optionally carry a
fused benzene ring and which can be unsubstituted or substituted,
for example, with one or more and, in particular, one to three
substituents selected from halogen, alkyl, hydroxy, alkoxy,
haloalkyl, nitro, amino, acylamino, alkylthio, alkylsulfinyl and
alkylsulfonyl.
[0033] The term "halogen" is defined herein to include fluorine,
chlorine, bromine and iodine.
[0034] The terms "linear and cyclic heteroalkyl" are defined in
accordance with the term "alkyl" with the suitable replacement of
carbon atoms with some other atom such as nitrogen or sulphur which
would render a chemically stable species.
[0035] Additionally, the functional groups mentioned above have
been set forth with parenthetical designations "( )" surrounding
certain atoms or groups of atoms where it seemed desireable to
elucidate molecular structure or bonding schemes. In particular, a
single atom such as "O" or a group of atoms such as "NH.sub.2" may
be presented in parentheses within the formula of one of the
functional groups set forth above [see, for example, when R.sup.7
is . . . --C(O)R.sup.12, --C(O)OR.sup.12, --C(O)NR.sup.12OR.sup.13,
--C(NH.sub.2)(NOR.sup.12), etc.] In such a situation, the
parentheses are intended to illustrate that the atom or groups of
atoms contained therein are bonded to the nearest preceeding
chemically suitable atom which is not surrounded by
parentheses.
[0036] More particularly, for example, --C(O)R.sup.12 is intended
to represent a functional group wherein the oxygen is bonded to the
carbon, the nearest preceeding atom which is not surrounded by
parentheses and is chemically suited for bonding according to
classical orbital electron bonding theory. Alternatively,
--C(NH.sub.2)(NOR.sup.12) is intended to represent a functional
group wherein the nitrogen present in both NH.sub.2 and NOR.sup.12
is bonded to the carbon, the nearest preceeding atom which is not
surrounded by parentheses. These examples are illustrated in (a)
and (b) below. Those skilled in the art will recognize that the
appropriate bonding schemes (e.g. single, double, etc) are evident
from the rules of orbital bonding. 5
[0037] Additionally, some of the functional groups mentioned above
have been set forth with parenthetical designations "( )"
surrounding certain atoms or groups of atoms wherein the
parentheses are immediately followed with an alphabetical or
numerical subscript [see, for example, when R.sup.7 is . . .
--CONR.sup.12(CH.sub.2).sub.qOCH.sub.3]. In such a situation, it is
intended that the atom or groups of atoms contained therein are
present within the functional group as multiples of the subscript.
For example, if q=2 when R.sup.7 is --CONR.sup.12(CH.sub.2).su-
b.qOCH.sub.3, then
R.sup.7=--CONR.sup.12CH.sub.2CH.sub.2OCH.sub.3.
[0038] Those skilled in the art will recognize that stereocenters
exist in compounds of Formula (I). Accordingly, the present
invention includes all possible stereoisomers and geometric isomers
of Formula (I) and includes not only racemic compounds but also the
optically active isomers as well. When a compound of Formula (I) is
desired as a single enantiomer, it may be obtained either by
resolution of the final product or by stereospecific synthesis from
either isomerically pure starting material or any convenient
intermediate. Resolution of the final product, an intermediate or a
starting material may be effected by any suitable method known in
the art. See, for example, Stereochemistry of Carbon Compounds by
E. L. Eliel (Mcgraw Hill, 1962) and Tables of Resolving Agents by
S. H. Wilen. Additionally, in situations where tautomers of the
compounds of Formula (I) are possible, the present invention is
intended to include all tautomeric forms of the compounds.
[0039] Some specific compounds of Formula (I) are listed below, the
synthesis of which was performed in accordance with the Example
section set forth below.
[0040] Compound No.
[0041] 1. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl
acrylamide.
[0042] 2. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl
propionamide.
[0043] 3.
2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]cyclopropanecarboxylic acid
diethylamide.
[0044] 4. 3-[4-(1,2-Diphenyl-but- 1-enyl)-phenyl]-N,
N-diethyl-2-methyl-acrylamide.
[0045] 5. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-but-2-enoic acid
diethylamide.
[0046] 6. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid
methyl ester.
[0047] 7. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylonitrile.
[0048] 8. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid
tert-butyl ester.
[0049] 9. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid.
[0050] 10.
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-1-morpholin-4-yl-prop-2--
en-1-one.
[0051] 11.
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-(3-methoxy-propyl)-acr-
ylamide.
[0052] 12. N,N-Dicyclohexyl-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]
acrylamide.
[0053] 13.
N-(2-Dimethylamino-ethyl)-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl-
]-N-ethyl acrylamide.
[0054] 14. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-methyl-N-octyl
acrylamide.
[0055] 15. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]acrylamide.
[0056] 16. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-ethyl
acrylamide.
[0057] 17.
1-Amino-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-prop-2-ene-1-one
oxime.
[0058] 18.
3-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-5-methyl-[1,2,-
4]-oxadiazole.
[0059] 19.
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-prop-2-ene-1-ol.
[0060] 20.
{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-allyl}-dimethylamine.
[0061] 21. 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl
thioacrylamide.
[0062] 22.
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-(3-hydroxy-propyl)-acr-
ylamide.
[0063] Generally, compounds of Formula (I) can be prepared
according to the following synthesis schemes. In all of the schemes
described below, it is well understood in the art that protecting
groups should be employed where necessary in accordance with
general principles of chemistry. These protecting groups are
removed in the final steps of the synthesis under basic, acidic, or
hydrogenolytic conditions which will be readily apparent to those
skilled in the art. By employing appropriate manipulation and
protection of any chemical functionalities, synthesis of any
compounds of the Formula (I) not specifically set forth herein can
be accomplished by methods analogous those illustrated in Schemes
B-G set forth below as well as the methods described in the Example
section.
[0064] Generally, the synthesis employed to yield the compounds of
the present invention was designed to give access to analogs of the
B-ring with the E-configuration of the central tetra-substituted
double bond. One method for the preparation of compounds having
Formula (I) incorporates Scheme B as set forth below wherein a
suitable bromide, such as bromide (b) [e.g.
(E)-1-Bromo-2-phenyl-1-(trimethylsilyl)-1-butene], is synthesized
in multi-gram quantities from acetylene (a) using the method of
Miller ( see Miller, R. B.; Al-Hassan, M. I. Stereospecific
Synthesis of (2)-Tamoxifen via Carbometalation of Alkynylsilanes.
J. Org. Chem. 1985, 50, 2121-2123). The bromide (b) is coupled with
a suitable aryl boronic acid, such as (c), under palladium
catalysis to yield the desired aldehyde (d) [e.g.
(Z)-1,2-Diphenyl-1-(4-formylphenyl)-1-butene], as a single isomer.
Bromide (b) and aldehyde (d) are versatile intermediates for the
synthesis of B-ring tamoxifen analogs. 6
[0065] As illustrated below in Scheme C, the coupling of bromide
(b) with aryl boronic acid (e) gives a,b-unsaturated diethyl amide
(g), which is Compound No. 1 as listed above and exemplified below
in Example 2. It should be noted that synthesis of this diethyl
amide by such route may likely result in a in low yield possibly
due to the thermal instability of aryl boronic acid (e). It was
also noted during the development of the compounds of the present
invention that the identification of diethyl amide (g) as a
compound of interest (i.e. Compound No.1:
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl acrylamide)
dictated the need for a more efficient synthesis for analog
preparation. Accordingly, it was found that Homer-Emmons reaction
of aldehyde (d) with phosphonate (f) gave diethyl amide (g) in
significantly higher yield. 7
[0066] Additionally, Scheme C set forth above illustrates that the
a,b-unsaturated diethyl amide (g) can be converted into:
[0067] (a). the thioamide (h), [Compound No.21:
3-[4-(1,2-Diphenyl-but-1-e- nyl)-phenyl]-N,N-diethyl
thioacrylamide], with Lawesson'Reagent;
[0068] (b). the saturated amide (i), [Compound No.2:
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl propionamide] by
hydrogenation; or
[0069] (c). the cyclopropyl amide (j), [Compound No.3:
2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]cyclopropanecarboxylic acid
diethylamide] with the Corey Ylide.
[0070] Referring to Scheme D set forth below, analogs of diethyl
amide (g) incorporating a trisubstituted a,b-unsaturated double
bond may be synthesized from a suitable aldehyde, such as (d), or a
suitable ketone, such as (n). More particularly, a Horner-Emmons
reaction of methyl phosphonate (k) with aldehyde (d) can be
employed to give the a-methyl amide (I) [Compound No. 4:
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-die-
thyl-2-methyl-acrylamide] as a single isomer and the reaction of
phosphonate (f) with ketone (n) may be employed to give a mixture
of E and Z-b-methyl amides (o,p) [Compound No. 5:
3-[4-(1,2-Diphenyl-but-1-eny- l)-phenyl]-but-2-enoic acid
diethylamide--(2) and (E) isomers] which can be separated by flash
chromatography with their relative stereochemistry being assigned
by subsequent .sup.1H NMR NOE studies. 8
[0071] Referring to Scheme E set forth below, carboxylic acid (r)
[Compound No. 9: 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic
acid] can be derived by saponification of methyl ester (q)
[Compound No. 6: 3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic
acid methyl ester], which, in turn, can be synthesized from
condensation of aldehyde (d) with trimethyl phosphonoacetate as
exemplified in Scheme D. Scheme E also illustrates how carboxylic
acid (r) may be employed as the key intermediate for the synthesis
of a diverse series of a,b-unsaturated amides following coupling to
a series of linear and cyclic, alkyl and heteroalkyl amines. 9
[0072] Referring to Scheme F set forth below, oxadiazole (v)
[Compound No. 18:
3-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-5-methyl-[1,2,4]-oxa-
diazole] may be synthesized from nitrile (t) [Compound No. 7:
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-10 acrylonitrile] by
reaction with hydroxylamine to give amide oxime (u) [Compound No.
18:
3-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-5-methyl-[1,2,4]-oxadiaz-
ole] followed by cyclization with acetic anhydride. 10
[0073] Referring to Scheme G as set forth below, alcohol (x)
[Compound No. 19: 3-[4-(1,2-Diphenyl-but-1-phenyl]-prop-2-ene-1-ol]
and dimethyl amine (y) [Compound No. 20:
{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-allyl}-dime- thylamine] may
be synthesized from t-butyl ester (w) [Compound No. 8:
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid tert-butyl
ester] by hydride reduction followed by mesylation and alkylation
with dimethyl amine. 11
GENERAL PROCEDURES
[0074] Unless otherwise noted all starting materials were obtained
from commercial suppliers and used without further purification.
Melting points were determined in capillary tubes on a Mel-Temp
apparatus and are uncorrected. .sup.1 H NMR and .sup.13C NMR
spectra were obtained on Varian Unity-300 and Varian XRL-300
spectrometers with TMS as an internal standard in CDCl.sub.3.
Chemical shifts are given in ppm (s); multiplicities are indicated
by s (singlet), d (doublet), t (triplet), q (quartet), m
(multiplet), br (broadened). Coupling constants (J) are reported in
Hz. Microanalyses were performed at Atlantic Microlabs, Inc. and
all values were within.+-.0.4% of the theoretical values. Mass
spectra were recorded on a JEOL JMS-AX505HA Mass Spectrometer with
Fast Atom Bombardment ionization. Infrared spectra were recorded on
a Perkin-Elmer 1280 infrared Spectrometer. Analytical thin-layer
chromatography was performed on EM Science silica 60 F254 glass
coated plates, and visualization was accomplished by UV light,
iodine, or ammonium molybdate. Flash chromatography was performed
with EM Science 230-400 mesh silica gel. MPLC was performed on a
Pharmacia LKB Series system using a Rainin Dynamax UV--C detector
and a Merck Lobar Si60 (40-63 mm) silica gel column. HPLC was
performed on a Shimadzu LC-6A Series HPLC using either a Rainin
Dynamax C.sub.18 RP column or a Rainin Dynamax Silica column. All
solvents were of reagent grade and used without further
purification. (E)-1-Bromo-2-phenyl-1-(trimethylsilyl)-1-b- utene
[see (b),Scheme B, supra] was prepared by the method of Miller as
referenced above and 4-formylboronic acid was prepared by the
method of Noth (see Feulner, H.; Linti, G.; Noth, H. Preparation
and Structural Characterization of p-Formylbenzeneboronic Acid.
Chem. Ber. 1990, 123,1841-1843. Boronic acids [see (e) and (m),
Schemes C and D, respectively] were prepared at Glaxo Group
Research Ltd., Hertfordshire, UK from
3-(4-Bromophenyl)-N,N-diethylacrylamide and 4-Bromoacetophenone
respectively using the method of Gilman (see Gilman, H.; Santucci,
L; Swayampati, D. R.; Ranck, R. O. Hydroxybenzeneboronic Acids and
Anhydrides. J. Am. Chem. Soc. 1957, 79, 3077-3082.
EXAMPLES
[0075] The following compounds were prepared according to the
general synthesis procedures set forth above and are provided
herein to better illustrate the how to make various compounds of
the present invention. The following Examples are illustrative and
not intended to limit the scope of the present invention .
Example 1
(2)-1,2-Diphenyl-1-(4-formylphenyl)-1-butene
[0076] A solution of 1.0 g (3.5 mmol) of
(E)-1-Bromo-2-phenyl-1-(trimethyl- silyl)-1-butene, 625 mg (4.2
mmol, 1.2 equiv) of boronic acid [see (c), Scheme B] and 400 mg
(0.35 mmol, 0.1 equiv) of Pd(PPh.sub.3).sub.4 in 10 mL of DME was
treated with 2 mL of 2 N Na.sub.2CO.sub.3 and then refluxed for 6
h. The solution was cooled to PT, poured into NaHCO.sub.3 (40 mL),
extracted with ethyl acetate (2.times.40 mL), dried (MgSO.sub.4),
and the solvent was removed in vacuo. Purification by silica gel
flash chromatography using hexane/ethyl acetate 20/1 as eluent
afforded 700 mg (69%) of the desired compound named above as a
yellow solid: .sup.1H NMR (CDCl.sub.3, 300 MHz) s 9.82 (s, 1 H),
7.55-7.00 (m, 14 H), 2.48 (q, 2 H), 0.97 (t, 3 H); low resolution
MS m/e 313 (MH.sup.+). [see, for example (d), Scheme B, supra].
Example 2
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl acrylamide
[0077] Procedure A A solution of 51 mg (0.18 mmol, 1.1 equiv) of
(E)-1-Bromo-2-phenyl-1-(trimethylsilyl)-1-butene, 40 mg (0.16 mmol)
of an aryl boronic acid [see (e), Scheme C], and 20 mg (16.2 mmol,
0.1 equiv) of Pd(PPh.sub.3).sub.4 in 5 mL of DME was treated with
0.5 mL of 2 N Na.sub.2CO.sub.3 and then refluxed for 2 h. The
solution was cooled to RT, poured into NaHCO.sub.3 (20 mL),
extracted with ethyl acetate (2.times.20 mL), dried (MgSO.sub.4),
and the solvent was removed in vacuo. Purification by silica gel
flash chromatography using hexane/ethyl acetate 3/1 as eluent
afforded 10 mg (15%) of the desired compound named above as a white
solid: m.p. 138-140.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s
7.53 (d, 1 H, J=15.4), 7.38-7.11 (m, 12 H), 6.86 (d, 2 H, J=8.3),
6.66 (d, 1 H, J=15.4), 3.40 (m, 4 H), 2.47 (q, 2 H, J=7.3), 1.19
(m, 6 H), 0.93 (t, 3 H, J=7.3); High Resolution MS Calc. 410.2483,
Found 410.2484.
[0078] Procedure B Use of Diethyl
Diethylcarbamoylmethylenephosphonate [see (f), Scheme C] as stated
in the general procedure for Horner-Emmons coupling (see Example 7,
infra) with the aldehyde,
(Z)-1,2-Diphenyl-1-(4-formylphenyl)-1-butene, followed by
purification using silica gel flash chromatography using a gradient
of hexane/ethyl acetate 20/1 to 2/1 as eluent afforded 110 mg (42%)
of the desired compound named above as a white solid: m.p.
137-138.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.53 (d, 1
H, J=15.4), 7.36-7.11 (m, 12 H), 6.86 (d, 2 H, J=8.3), 6.66 (d, 1
H, J=15.4), 3.42 (m, 4 H), 2.47 (q, 2 H, J=7.3), 1.19 (m, 6 H),
0.93 (t, 3 H, J=7.3); Anal. (C.sub.29H.sub.31NO) C, H, N. [see, for
example (g), Scheme C, supra].
Example 3
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl
thioacrylamide
[0079] A mixture of 65 mg (0.16 mmol) of
3-[4-(1,2-Diphenyl-but-1-enyl)-ph- enyl]-N,N-diethyl acrylamide
(see Example 2) and 39 mg (95.2 mmol, 0.6 equiv) of Lawesson's
reagent were heated in 2 mL dry toluene at 85.degree. C. for 2 h.
The solution was cooled to RT and placed directly on a silica gel
flash chromatography column. Purification by elution with
hexane/ethyl acetate 10/1 afforded 54 mg (83%) of thioamide of the
desired compound named above as a yellow foam: m.p. 43-61.degree.
C.; .sup.1H NMR (CDCl.sub.3,300 MHz) s 7.85 (d, 0.5 H), 7.75 (d,
0.5 H), 7.65 (d, 0.5 H), 7.40-6.80 (m, 13.5 H), 4.05 (m, 2 H), 3.70
(m, 2 H), 2.45 (m, 2 H), 1.30 (m, 6 H), 0.95 (m, 3 H); .sup.13C NMR
(CDCl.sub.3, 75 MHz) s 193.83, 144.56, 143.96, 143.18, 143.11,
141.92, 138.26, 133.00, 131.22, 130.83, 129.66, 128.28, 128.01,
127.91, 127.86, 127.70, 127.48, 127.02, 126.83, 126.45, 124.04,
48.54, 46.40, 29.19, 13.86, 13.67, 13.62, 11.66; IR (CHCl.sub.3)
3050, 1520, 1210, 950, 750; Anal. (C.sub.29H.sub.31NS) C, H, N.
[see, for example (h), Scheme C, supra].
Example 4
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl propionamide
[0080] A solution of 50 mg (0.12 mmol) of
3-[4-(1,2-Diphenyl-but-1-enyl)-p- henyl]-N,N-diethyl acrylamide
(see Example 2) and 3 mg of tris(triphenylphosphine)-rhodium(l)
chloride (Wilkinson's catalyst) in 1 mL dry toluene was stirred
over an atmosphere of H.sub.2 gas at 50.degree. C. for 16 h. The
solution was cooled to RT and the toluene removed in vacuo.
Purification of the residue by silica gel flash chromatography
using hexane/ethyl acetate 2/1 as eluent afforded 48 mg (95%) of
the desired compound named above of the desired compound named
above as a clear, colorless oil: .sup.1H NMR (CDCl.sub.3, 300 MHz)
s 7.37-7.11 (m, 10 H), 6.85 (d, 2 H, J=8.3), 6.78 (d, 2 H, J=8.3),
3.31 (q, 2 H, J=7.1), 3.08 (q, 2 H, J=7.3), 2.81 (t, 2 H, J=8.3),
2.44 (m, 4 H), 1.03 (m, 6 H), 0.91 (t, 3 H, J=7.3); low resolution
MS m/e 412 (MH.sup.+); Anal. (C.sub.29H33NO) C, H, N. [see, for
example (I), Scheme C, supra].
Example 5
2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl] cyclopropanecarboxylic acid
diethylamide
[0081] A solution of 12 mg (0.24 mmol, 2.0 equiv) of sodium hydride
(50% in oil) and 54 mg (0.24 mmol, 2.0 equiv) of
trimethyloxosulfonium iodide in 2 mL dry dimethyl sulfoxide was
stirred 30 min at RT, at which time gas evolution had ceased to
occur. A solution of 50 mg (0.12 mmol) of the amide as prepared in
Example 2 in 0.5 mL dimethyl sulfoxide was then added and the
resulting solution heated to 50.degree. C. for 16 h. The reaction
mixture was cooled to RT, poured into 20 mL H.sub.2O, and extracted
with ethyl acetate (2.times.20 mL). The organic layers were
combined, dried (MgSO.sub.4), and the solvent removed in vacuo.
Purification of the residue by silica-gel MPLC using hexane/ethyl
acetate 4/1 as eluent afforded 32 mg (62%) of the desired compound
named above as a white solid: m.p. 42-44.degree. C.; .sup.1H NMR
(CDCl.sub.3, 300 MHz) s 7.37-7.10 (m, 10 H), 6.76 (m, 4 H), 3.38
(q, 4 H, J=7.1), 2.45 (q, 2 H, J=7.4), 2.30 (m, 1 H), 1.79 (m, 1
H), 1.55 (m, 1 H), 1.11 (m, 7 H), 0.92 (t, 3 H, J=7.4); low
resolution MS m/e 424 (MH.sup.+); Anal. (C.sub.30H.sub.33NO) C, H,
N. [see, for example (j), Scheme C, supra].
Example 6
(methyl) Diethyl Diethylcarbamoylmethylenephosphonate
[0082] A solution of 4.4 mL (2.2 mmol, 1.1 equiv) of KN(TMS).sub.2
(0.5 M in toluene) was added to a cold (-78.degree. C.) solution of
500 mg (2.0 mmol) Diethyl Diethylcarbamoylmethylenephosphonate in 5
mL dry THF. The resulting solution was stirred 10 min, then 0.15 mL
(2.4 mmol, 1.2 equiv) of methyl iodide was added neat. The
resulting solution was allowed to warm to RT and stirred 1 h, then
poured into brine (70 mL) and extracted with ethyl acetate
(2.times.60 mL). The organic layers were combined, dried
(MgSO.sub.4), and the solvent removed in vacuo. Purification of the
yellow residue via Kugelrohr distillation afforded 525 mg (100%) of
the desired compound named above as a clear, colorless oil: b.p.
155.degree. C. at 0.15 torr; .sup.1H NMR (CDCl.sub.3, 300 MHz) s
4.18 (m, 4 H), 3.60 (m, 1 H), 3.22 (m, 4 H), 1.37 (m, 9 H), 1.18
(m, 6 H). [see, for example (k), Scheme C, supra].
Example 7
General Procedure for Horner-Emmons reactions with
(Z)-1.2-Diphenyl-1-(4-f- ormylphenyl)-1-butene.
[0083] A solution of 1.2 equiv of KN(TMS).sub.2 (0.5 M in toluene)
was added to a stirring 0.degree. C. solution of 1.2 equiv. of the
appropriate phosphonate in dry THF. The resulting solution was
stirred 15 min. at 0.degree. C., then cooled to -78.degree. C. and
a solution of (Z)-1,2-Diphenyl-1-(4-formylphenyl)-1-butene in THF
was added dropwise. The resulting solution was allowed to warm to
RT and stirred 4 h, then warmed to 50.degree. C. for 2 h to ensure
reaction completion. The reaction mixture was cooled to RT, poured
into brine, and extracted twice with ethyl acetate. The organic
layers were combined, dried (MgSO.sub.4), the solvent was removed
in vacuo, and the residue purified by silica gel flash
chromatography.
Example 8
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N,N-diethyl-2-methyl-acrylamide
[0084] Use of (Methyl) Diethyl Diethylcarbamoylmethylenephosphonate
as employed above followed by purification via silica gel flash
chromatography using hexane/ethyl acetate 3/1 as eluent afforded 36
mg (53%) of of the desired compound named above as a clear
colorless oil: .sup.1H NMR (CDCl.sub.3,300 MHz) s 7.39-7.11 (m, 10
H), 6.97 (d, 2 H, J=8.0), 6.85 (d, 2 H, J=8.3), 6.32 (s, 1 H), 3.38
(m, 4 H), 2.47 (q, 2 H, J=7.3), 2.00 (s, 3 H), 1.14 (t, 6 H,
J=7.1), 0.93 (t, 3 H, J=7.3); low resolution MS m/e 424; Anal.
(C.sub.30H.sub.33NO) C, H, N. [see, for example (1), Scheme D,
supra].
Example 9
(Z)-and (E)-3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-but-2-enoic acid
diethylamide
[0085] Use of Diethyl Diethylcarbamoylmethylenephosphonate as
employed above with purification by silica gel flash chromatography
using hexane/ethyl acetate 5/2 afforded 95 mg (49%) of the
LZ-isomer of the desired compound named above as a white solid and
11 mg (6%) of the (E)-isomer as a colorless oil. Analytical data
for the (Z)-isomer: m.p. 109-111.degree. C.; .sup.1H NMR
(CDCl.sub.3, 300 MHz) s 7.39-7.09 (m, 12 H), 6.85 (d, 2 H, J=8.3),
6.20 (d, 1 H, J=1.0), 3.44 (q, 2 H, J=7.1), 3.33 (q, 2 H, J=7.1),
2.47 (q, 2 H, J=7.5), 2.16 (d, 3 H, J=1.0), 1.13 (m, 6 H), 0.93 (t,
3 H, J=7.6); low resolution MS m/e 424; Anal. (C.sub.30H.sub.33NO)
C, H, N. Analytical data for the (E)-isomer: .sup.1H NMR
(CDCl.sub.3, 300 MHz) s 7.36-7.09 (m, 10 H), 7.00 (d, 2 H, J=8.3),
6.81 (d, 2 H, J=8.2), 5.80 (d, 1 H, J=1.0), 3.22 (q, 2H, J=7.2),
2.91 (q, 2 H, J=7.1), 2.45 (q, 2 H, J=7.6), 2.04 (d, 3 H, J=1.0),
0.89 (m, 6 H), 0.74 (t, 3 H, J=7.6); low resolution MS m/e 424.
[see, for example (o,p), Scheme D, supra].
Example 10
3-[4-(1.2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid methyl
ester
[0086] Use of Trimethyl phosphonoacetate as set forth above
followed by purification using silica gel flash chromatography
using hexane/ethyl acetate 20/1 as eluent afforded 2.33 g (100%) of
the desired compound named above as a white solid: m.p.
133-135.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.53 (d, 1
H, J=16.0), 7.39-7.10 (m, 12 H), 6.88 (d, 2 H, J=8.3), 6.27 (d, 1
H, J=16.0), 3.76 (s, 3 H), 2.48 (q, 2 H, J=7.3), 0.93 (t, 3H,
J=7.3); low resolution MS m/e 369; Anal. (C.sub.26H.sub.24O.sub.2)
C, H, N. [see, for example (q), Scheme E, supra].
Example 11
3-[4-(1 .2-Diphenyl-but-1-enyl)-phenyl]-acrylonitrile
[0087] Use of Diethyl cyanomethylphosphonate as set forth above
with purification by silica gel flash chromatography using
hexane/ethyl acetate 10/1 as eluent afforded 125 mg (93%) of the
desired compound named above as a clear, colorless oil which
solidifies upon standing: m.p. 101-102.degree. C.; .sup.1H NMR
(CDCl.sub.3, 300 MHz) s 7.40-7.07 (m, 13 H), 6.90 (d, 2 H, J=8.6),
5.79 (d, 1 H, J=16.6), 2.48 (q, 2 H, J=7.3), 0.93 (t, 3 H, J=7.3);
Anal. (C.sub.25H.sub.21 N) C, H, N. [see, for example (t), Scheme
F, supra].
Example 12
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid tert-butyl
ester
[0088] Use of t-butyl diethylphosphonoacetate as set forth above
with purification by silica gel flash chromatography using
hexane/ethyl acetate 20/1 as eluent then recrystallization from hot
hexane afforded 52 mg (95%) of the desired compound named above as
a white solid: m.p. 139-140.degree. C.; .sup.1H NMR (CDCl.sub.3,
300 MHz) s 7.44-7.09 (m, 13 H), 6.86 (d, 2 H, J=8.3), 6.20 (d, 1 H,
J=16.1), 2.47 (q, 2 H, J=7.4), 1.49 (s, 9 H), 0.93 (t, 3 H, J=7.4);
low resolution MS m/e 373, no MH.sup.+; Anal.
(C.sub.29H.sub.30O.sub.2) C, H. [see, for example (w), Scheme G,
supra].
Example 13
1-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-ethanone
[0089] A solution of 172 mg (0.60 mmol) of
(E)-1-Bromo-2-phenyl-1-(trimeth- ylsilyl)-1-butene [see (b),Scheme
B, supra], 125 mg (0.60 mmol, 1.0 equiv) of boronic acid [see (m),
Scheme D] and 70 mg (0.06 mmol, 0.1 equiv) of Pd(PPh.sub.3)4 in 8
mL of DME was treated with 0.4 mL of 2 N Na.sub.2CO.sub.3 and then
refluxed for 18 h. The solution was cooled to RT, poured into brine
(20 mL), extracted with ethyl acetate (2.times.20 mL), dried
(MgSO.sub.4), and the solvent was removed in vacuo. Purification by
silica gel flash chromatography using hexane/ethyl acetate 20/1 as
eluent afforded 152 mg (78%) of the desired compound named above as
a yellow solid: .sup.1H NMR, (CDCl.sub.3, 300 MHz) s 7.6 (d, 2 H),
7.45-7.10 (m, 10 H), 6.98 (d, 2 H), 2.48 (m, 3 H), 0.94 t, 3-H).
[see, for example (n), Scheme D, supra].
Example 14
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acrylic acid
[0090] A solution of 50 mL (16 mmol, 10.0 equiv.) of 0.2 M KOH was
added dropwise over 2 minutes to a solution of 600 mg of the ester
as prepared in Example 10(1.6 mmol, 1.0 equiv.) in 90 mL of
methanol/THF 1/2. The resulting solution was stirred 18 h at RT and
the solvent was removed in vacuo. The residue was dissolved in 30
mL of 1 M HCl and extracted with ethyl acetate (2.times.60 mL). The
organic layers were combined, dried (MgSO.sub.4), and the solvents
removed in vacuo. Purification of the residue by silica gel flash
chromatography using methylene chloride/methanol 95/5 as eluent
provided 370 mg (63%) of the desired compound named above as a
white solid: m.p. 148-150.degree. C.; .sup.1H NMR (CDCl.sub.3, 300
MHz) s 7.60 (d, 1 H, J=15.9), 7.39-7.10 (m, 12 H), 6.89 (d, 2 H,
J=8.1), 6.27 (d, 1 H, J=15.9), 2.48 (q, 2 H, J=7.3), 0.93 (t, 3 H,
J=7.3); low resolution MS m/e 355; Anal. (C.sub.25H.sub.22O.sub.-
2) C, H. [see, for example (r), Scheme E, supra].
Example 15
General Procedure for Coupling Reactions with
3-[4-(1,2-Diphenyl-but-1-eny- l)-phenyl]-acrylic acid
[0091] To a solution of 1.0 equiv of acid (20) in dry methylene
chloride was added 1.0 equiv. of EDC, 1.3 equiv. of HOBT and 1.0
equiv. of Et3N followed by 1.2 equiv. of the appropriate amine. The
resulting solution was stirred 18 h at RT, then poured into 20 mL
of H.sub.2O, and extracted twice with ethyl acetate (2.times.60
mL). The organic layers were combined, washed with H.sub.2O
(1.times.20 mL), dried (MgSO.sub.4), the solvent was removed in
vacuo, and the residue purified by silica gel flash chromatography,
silica gel MPLC, or by recrystallization.
Example 16
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-1-morpholin-4-yl-prop-2-en-1-one
[0092] Use of morpholine followed by purification by silica gel
MPLC using hexane/ethyl acetate 2/1 as eluent followed by
recrystallization from hot hexane afforded 12 mg (14%) of the
desired compound named above as a white solid: m.p. 150-154.degree.
C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.53 (d, 1 H, J=15.4),
7.39-7.10 (m, 12 H), 6.87 (d, 2 H, J=8.3), 6.67 (d, 1 H, J=15.4),
3.65 (m, 8 H), 2.48 (q, 2 H, J=7.3), 1.26 (broad, 8 H), 0.93 (t, 3
H, J=7.3); low resolution MS m/e 424; Anal.
(C.sub.29H.sub.29NO.sub.2) C, H, N. [see, for example (s), Scheme
E, supra].
Example 17
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-(3-methoxy-propyl)-acrylamide
[0093] Use of 3-methoxypropylamine followed by purification by
recrystallization from hot hexane/ethyl acetate 2/1 followed by
silica gel MPLC using hexane/ethyl acetate 1/2 as eluent afforded
20 mg (30%) of the desired compound named above as a white solid:
m.p. 132-135.degree. C.; 1H NMR (CDCl.sub.3, 300 MHz) s 7.43 (d,
1H, J=15.7), 7.36-7.10 (m,12 H), 7.86 (d, 2 H, J=8.3), 6.20 (d, 1
H, J=15.7), 3.46 (m, 4 H), 3.34 (s,1 H), 2.48 (q, 2 H, J=7.5), 1.80
(m, 2 H), 0.92 (t, 3 H, J=7.5); low resolution MS m/e 426; Anal.
(C.sub.29H.sub.31 NO.sub.2) C, H, N. [see, for example (s), Scheme
E, supra].
Example 18
N,N-Dicyclohexyl-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]acrylamide
[0094] Use of dicyclohexylamine followed by purification by
recrystallization from hot hexane/ethyl acetate 2/1 afforded 29 mg
(28%) of the desired compound named above as a white solid: m.p.
194-200.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.43-7.11
(m, 13 H), 6.86 (d, 2 H, J=8.3), 6.69 (d, 1 H, J 15.4), 3.50 (m, 2
H), 2.48 (q, 2 H, J=7.3), 2.25 (m, 2 H), 1.77-1.62 (2 m, 12 H),
1.30-1.10 (m, 8 H), 0.93 (t, 3 H, J=7.3); low resolution MS m/e
518; Anal. (C.sub.37H.sub.43NO) C, H, N. [see, for example (s),
Scheme E, supra].
Example 19
N-(2-Dimethylamino-ethyl)-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-N-ethyl
acrylamide hydrogen oxalate
[0095] Use of 2-dimethylaminoethylamine followed by purification by
silica gel flash chromatography using methylene chloride/methanol
15/1 as eluent followed by formation of the hydrogen oxalate salt
with 1.1 equiv. of oxalic acid in Et.sub.2O afforded 58 mg (53%) of
the desired compound named above as a white solid: m.p.
145-147.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.51 (d, 1
H, J=15.1), 7.38-7.10 (m, 12 H), 6.88 (d, 2 H), 6.60 (d, 1 H,
J=15.1), 6.12 (m, 2 H), 3.70 (m, 2 H), 3.47 (m, 3 H), 3.35 (m, 2
H), 2.90 (m, 4 H), 2.48 (q, 2 H, J=7.4), 1.20 (m, 2 H), 0.93 (t, 3
H, J=7.4); low resolution MS m/e 453; Anal. (C.sub.31
H.sub.36N.sub.2O C.sub.2H.sub.2O.sub.4) C, H, N. [see, for example
(s), Scheme E, supra].
Example 20
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-(3-hydroxy-propyl)-acrylamide
[0096] Use of 3-hydroxypropylamine followed by purification by
silica gel MPLC using a gradient of hexane/ethyl acetate 2/1 to
100% ethyl acetate as eluent followed by recrystallization from hot
hexane afforded 14 mg (15%) of the desired compound named above as
a white solid: m.p. 144-146.degree. C.; .sup.1H NMR (CDCl.sub.3,
300 MHz) s 7.47 (d, 1 H, J=15.6), 7.36-7.10 (m, 12 H), 7.86 (d, 2
H, J=8.3), 6.22 (d, 1 H, J=15.6), 3.62 (m, 2 H), 3.51 (m, 2 H),
3.25 (t, 1 H), 2.47 (q, 2 H, J=7.3), 1.71 (m, 2 H), 0.94 (t, 3 H,
J=7.3); low resolution MS m/e 412; Anal. (C.sub.28H.sub.29NO.sub.2)
C, H, N. [see, for example (s), Scheme E, supra].
Example 21
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-methyl-N-octyl
acrylamide
[0097] Use of N-methyl-N-octylamine followed by purification by
silica gel MPLC using hexane/ethyl acetate 3/1 as eluent afforded
56 mg (41%) of the desired compound named above as a white solid:
m.p. 108-109.degree. C.; .sup.1H NMR (CDCl.sub.3,300 MHz) s 7.52
(d, 1 H, J=15.4), 7.38-7.14 (m, 12 H), 6.86 (d, 2 H, J=7.8), 6.68
(dd, 1 H, J=15.4), 3.00 (d, 4 H), 2.48 (q, 2 H, J=7.3), 1.26 (m, 8
H), 0.93 (t, 3 H, J=7.3), 0.86 (m, 6 H); low resolution MS m/e 480;
Anal. (C.sub.34H.sub.41NO) C, H, N. [see, for example (s), Scheme
E, supra].
Example 22
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl] acrylamide
[0098] Use of a saturated solution of ammonia in CH.sub.2Cl.sub.2
followed by purification by silica gel MPLC using hexane/ethyl
acetate 2/1 as eluent afforded 39 mg (39%) of the desired compound
named above as a white solid: m.p. 200-202.degree. C.; .sup.1H NMR
(CDCl.sub.3, 300 MHz) s7.47 (d, 1 H, J=15.6), 7.39-7.10 (m, 12 H),
6.87 (d, 2 H, J=8.3), 6.27 (d, 1 H, J=15.6), 2.48 (q, 2 H, J=7.3),
0.93 (t, 3 H, J=7.3); low resolution MS m/e 354; Anal.
(C.sub.25H.sub.23NO) C, H, N.
Example 23
3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-N-ethyl acrylamide
[0099] A solution of 0.2 mL (0.4 mmol, 1.2 equiv.) of oxalyl
chloride (2 M in CH.sub.2Cl.sub.2) was added to a stirring
0.degree. C. solution of 120 mg (0.3 mmol) of the acid as prepared
in Example 14 which was in 2 mL of dry methylene chloride. The
resulting solution was allowed to warm to RT and stirred overnight.
The solvent was removed in vacuo and the residue dissolved in 2 mL
of ether and then added to a rapidly stirring solution of 23 mL of
ethylamine (70% wt. in H.sub.2O) (0.4 mmol, 1,2 equiv.) in 2 mL of
1M NaOH. The resulting solution was stirred at RT for 2 h. The
reaction mixture was poured into ethyl acetate and extracted; the
aqueous layer was washed with ethyl acetate (3.times.10 mL). The
organic layers were combined, dried (MgSO.sub.4), the solvent was
removed in vacuo, and the residue purified by recrystallization
from hot ethyl acetate to afford 45 mg (35%) of the desired
compound named above as a white solid; m.p. 192-193.degree. C.;
.sup.1H NMR (CDCl.sub.3, 300 MHz) s7.45 (d, 1 H, J=15.6), 7.39-7.10
(m, 12 H), 6.86 (d, 2 H, J=8.1), 6.20 (d, 1 H, J=15.6), 3.38 (m, 2
H, J=7.3), 2.48 (q, 2 H, J=7.3), 1.17 (t, 3 H, J=7.3), 0.93 (t, 3
H, J=7.3); low resolution MS m/e 382; Anal. (C.sub.27H.sub.27NO) C,
H, N. [see, for example (s), Scheme E, supra].
Example 24
[0100]
1-Amino-3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-prop-2-ene-1-one
oxime
[0101] A solution of 1.16 mL (1.16 mmol, 3.1 equiv) of sodium
methoxide in methanol (1.0 M) was added to a solution of 78 mg
(1.12 mmol, 3.0 equiv) of hydroxylamine hydrochloride in 4 mL dry
methanol. The resulting solution was refluxed for 15 min., then
cooled to RT. A solution of 125 mg (0.37 mmol) of a nitrile as
prepared in Example 11 which was in 2 mL of dry methanol/THF 2/1
was added, and the reaction mixture was refluxed for 16 h. The
reaction was cooled, poured into 20 mL brine and extracted with
ethyl acetate (2.times.20 mL), dried (MgSO.sub.4), and the solvents
were removed in vacuo. Purification by silica gel flash
chromatography afforded 61 mg (47%) of the desired compound named
above as a white solid: m.p. 182-185.degree. C.; .sup.1H NMR
(CDCl.sub.3, 300 MHz) s 7.38-7.07 (m, 12 H), 6.85 (d, 2 H, J=8.0),
6.68 (d, 1 H, J=16.7), 6.32 (d, 1 H, J=16.7), 4.60 (s, br, 2 H),
2.47 (q, 2 H, J=7.6), 2.17 (s, 1 H), 0.93 (t, 3 H, J=7.6); low
resolution MS m/e 369; Anal. (C.sub.25H.sub.24N.sub.2O) C, H, N.
[see, for example (u), Scheme F, supra].
Example 25
3-{-2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-5-methyl-[1,2,4]-oxadiaz-
ole
[0102] A solution of 60 mg (0.16 mmol) of amide oxime as prepared
above in Example 24 which was in 5 mL of acetic anhydride was
heated at 80.degree. C. for 18 h, cooled to RT, poured into 10 mL 4
N NaOH and extracted with ethyl acetate (2.times.20 mL). The
organic layers were combined, dried (MgSO.sub.4), and the solvent
removed in vacuo. The crude material was purified by flash
chromatography using hexane/ethyl acetate 10/1 as eluent to afford
21 mg of slightly impure product, which was recrystallized from hot
methanol/ethyl acetate 10/1 to give 13 mg (20%) of the desired
compound named above as a white crystalline solid: m.p.
158-59.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.50 (d, 1
H, J=16.4), 7.37-7.12 (m, 13 H), 6.87 (m, 2 H), 2.58 (s, 3 H), 2.47
(q, 2 H, J=7.3), 0.93 (t, 3 H, J=7.3); low resolution MS m/e 392;
Anal. (C.sub.27H.sub.24N.sub.2O) C, H, N. [see, for example (v),
Scheme F, supra].
Example 26
3-4-( 1,2-Diphenyl-but-1-enyl)-phenyl-prop-2-ene-1-ol
[0103] A solution of 1.35 mL (1.35 mmol, 2.5 equiv) of 1.0 M
DIBAL-H in THF was added dropwise to a -78.degree. C. solution of
the ester as prepared above in Example 12 which was in 3 mL THF.
The resulting solution was stirred 30 min at -78.degree. C. then
warmed to RT and stirred 16 h. The excess DIBAL-H was quenched with
1 N HCl and the reaction mixture poured into 20 mL 1 N HCl and
extracted with ethyl acetate (2.times.20 mL). The organic layers
were combined, dried (MgSO.sub.4), and the solvents removed in
vacuo. Purification of the residue by silica gel flash
chromatography using hexane/ethyl acetate 5/1 as eluent provided 94
mg (60%) of the desired compound named above as a white solid: m.p.
80-83.degree. C.; .sup.1H NMR (CDCl.sub.3, 300 MHz) s 7.41-7.02 (m,
12 H), 6.82 (d, 2 H, J=8.3), 6.45 (d, 1 H, J=15.8), 6.23 (dt, 1 H,
J=5.8, 15.9), 4.24 (m, 2 H), 2.47 (q, 2 H, J=7.6), 1.31 (t, 1 H,
J=5.9), 0.93 (t, 3 H, J=7.6); low resolution MS m/e 340; Anal.
(C.sub.25H.sub.24O) C, H. [see, for example (x), Scheme G.
supra].
Example 27
{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-allyl}-dimethylamine
[0104] A solution of 90 mg (0.27 mmol) of the alcohol as prepared
above in Example 26 and 41 mg (0.32 mmol, 1,2 equiv) of
diisopropylethylamine in 2 mL dry dichloromethane was treated with
33 mg (0.29 mmol, 1.1 equiv) of methanesulfonyl chloride and the
resulting solution was stirred at RT for 3 h. The solution was then
poured into 10 mL of ethyl acetate and extracted with 10 mL of
brine, dried (MgSO.sub.4), and the solvents removed in vacuo to
provide 108 mg (97%) of a thick golden oil. This material was
immediately dissolved in 3 mL dry methanol and then 1-mL of
dimethylamine was added. The resulting solution was stirred 16 h at
RT then the solvents were removed in vacuo. The residue was
dissolved in 10 mL ethyl acetate and extracted with 1 N HCl. The
aqueous layer was separated and made basic by addition of 3 N NaOH
and then extracted with ethyl acetate (2.times.10 mL). The basic
extracts were combined, dried (MgSO.sub.4), and the solvent removed
in vacuo. Purification of the residue by silica gel MPLC using
dichloromethane/methanol 15/1 as eluent afforded 37 mg (40%) of the
desired compound named above as a clear, colorless oil: .sup.1H NMR
(CDCl.sub.3, 300 MHz) s 7.37-7.09 (m, 10 H), 7.02 (d, 2 H, J=8.5),
6.81 (d, 2 H, J=8.1), 6.34 (d, 1 H, J=15.9), 6.14 (dt, 1 H, J=6.6,
15.9), 3.17 (d, 2 H, J=6.6), 2.59-2.42 (m, 6 H), 1.01 (t, 6 H,
J=7.3), 0.92 (t, 3 H, J=7.4); low resolution MS m/e 396; Anal.
(C.sub.29H.sub.33N) C, H, N. [see, for example (y), Scheme G,
supra].
[0105] Compounds of Formula (I) which contain acidic moieties may
form pharmaceutically acceptable salts with suitable cations.
Suitable pharmaceutically acceptable cations include alkali metal
(e.g., sodium or potassium) and alkaline earth metal (e.g., calcium
or magnesium) cations. In light of the foregoing, any reference to
compounds of the present invention appearing herein is intended to
include both compounds of Formula (I) as well as pharmaceutically
acceptable salts and solvates thereof.
[0106] As previously mentioned, the compounds of the present
invention are useful for the treatment and/or prevention of a
variety of disorders or conditions such as cardiovascular disease,
breast cancer, osteoporosis and arthritic conditions. Some other
examples of disorders or conditions for which the compounds of the
present invention are also useful in treating and/or preventing
include premenstrual syndrome, vasomotor symptoms associated with
menopause, atrophic vagginitis, Kraurosis vulvae, female
hypogonadism, primary ovarian failure, excessive hair growth and
prostatic cancer.
[0107] It will be appreciated by those skilled in the art that
reference herein to treatment extends to prophylaxis as well as the
treatment of established diseases or symptoms. It will further be
appreciated that the amount of a compound of the invention required
for use in treatment will vary with the nature of the condition
being treated and the age and the condition of the patient and will
be ultimately at the discretion of the attendant physician or
veterinarian. In general, however, doses employed for adult human
treatment will typically be in the range of 0.001 mg/kg to about
100 mg/kg per day. The desired dose may conveniently be presented
in a single dose or as divided doses administered at appropriate
intervals, for example as two, three, four or more sub-doses per
day.
[0108] The present invention also provides for novel pharmaceutical
compositions of the compounds of Formula (I). While it is possible
that compounds of the present invention may be therapeutically
administered as the raw chemical, it is preferable to present the
active ingredient as a pharmaceutical formulation. Accordingly, the
present invention further provides for pharmaceutical formulations
comprising a compound of Formula (I) or a pharmaceutically
acceptable salt thereof together with one or more pharmaceutically
acceptable carriers and, optionally, other therapeutic and/or
prophylactic ingredients. The carrier(s) must be "acceptable" in
the sense of being compatible with the other ingredients of the
formulation and not deleterious to the recipient thereof.
[0109] Formulations of the present invention may be administered in
standard manner for the treatment of the indicated diseases, such
as orally, parenterally, sublingually, transdermally, rectally, via
inhalation or via buccal administration. For buccal administration,
the composition may take the form of tablets or lozenges formulated
in conventional manner. For example, tablets and capsules for oral
administration may contain conventional excipients such as binding
agents, (for example, syrup, accacia, gelatin, sorbitol,
tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers
(for example, lactose, sugar, microcrystalline cellulose,
maize-starch, calcium phosphate or sorbitol), lubricants (for
example, magnesium stearate, stearic acid, talc, polyethylene
glycol or silica), disintegrants (for example, potato starch or
sodium starch glycollate) or wetting agents, such as sodium lauryl
sulphate. The tablets may be coated according to methods well-known
in the art.
[0110] Alternatively, the compounds of the present invention may be
incorporated into oral liquid preparations such as aqueous or oily
suspensions, solutions, emulsions, syrups or elixirs, for example.
Moreover, formulations containing these compounds may be presented
as a dry product for constitution with water or other suitable
vehicle before use. Such liquid preparations may contain
conventional additives such as suspending agents such as sorbitol
syrup, methyl cellulose, glucose/sugar syrup, gelatin,
hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate
gel or hydrogenated edible fats; emulsifying agents such as
lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles
(which may include edible oils) such as almond oil, fractionated
coconut oil, oily esters, propylene glycol or ethyl alcohol; and
preservatives such as methyl or propyl p-hydroxybenzoates or sorbic
acid.
[0111] Such preparations may also be formulated as suppositories,
e.g., containing conventional suppository bases such as cocoa
butter or other glycerides. Compositions for inhalation can be
typically provided in the form of a solution, suspension or
emulsion that may be administered as a dry powder or in the form of
an aerosol using a conventional propellant such as
dichlorodifluoromethane or trichlorofluoromethane. Typical
transdermal formulations comprise a conventional aqueous or
non-aqueous vehicles, such as creams, ointments, lotions or pastes
or are in the form of a medicated plaster, patch or membrane.
[0112] Additionally, compositions the present invention may be
formulated for parenteral administration by injection or continuous
infusion. Formulations for injection may take such forms as
suspensions, solutions, or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient may
be in powder form for constitution with a suitable vehicle (e.g.,
sterile, pyrogen-free water) before use.
[0113] The composition according to the invention may also be
formulated as a depot preparation. Such long acting formulations
may be administered by implantation (for example, subcutaneously or
intramuscularly) or by intramuscular injection. Accordingly, the
compounds of the invention may be formulated with suitable
polymeric or hydrophobic materials (as an emulsion in an acceptable
oil, for example), ion exchange resins or as sparingly soluble
derivatives as a sparingly soluble salt, for example.
[0114] The biological activity of the compounds of Formula (I) was
evaluated according to the following protocols with the appropriate
resulting data being provided hereinbelow. In particular, the
compounds of Formula (I) may be evaluated for their osteoprotective
activity and their anti-uterotrophic profiles using the methods set
forth in the following protocols.
[0115] Those skilled in the art will appreciate that several
acceptable varieties of rat estrogen receptor binding assays are
known and available for initial screening of the compounds of the
present invention with respect to their ability to bind to the
appropriate receptor. Compounds were initially evaluated as set
forth below in an rat estrogen receptor binding assay for the
ability to inhibit the binding of [.sup.3H]-estradiol. Compounds
that displayed an IC.sub.50<10 .mu.M were progressed to an in
vitro functional assay of estrogenic activity in the Ishikawa human
endometrioma cell line as set forth below.
[0116] Subconfluent Ishikawa-Var I cells were removed from
maintenance growth conditions and resuspended in phenol red-free
DMEM-F12 containing 5% charcoal stripped FBS and 2 mM glutamine at
a concentration of 58,500 cells/mL. Cells were plated at a density
of 13,000 cells/cm.sup.2 and placed in an incubator (37.degree. C.,
5% CO.sub.2) for 3 days. Cells were harvested and resuspended in
phenol red-free DMEM-F12 containing 1% charcoal stripped FBS, 2 mM
glutamine, 100 Units/mL penicillin and 100 .mu.g/mL streptomycin to
a concentration of 83,000 cells/mL. Cells were seeded at a density
of 8300 cells/well in 96 well plates and allowed to attach
overnight. Appropriate drug treatments at 2.times. concentrations
were added in 0.1 mL of medium containing 0.2% DMSO. Plates were
incubated for 2 days, media was aspirated and plates washed once
with 300 .mu.L 0.9% sterile saline. Plates were frozen at
-70.degree. C. and then warmed to RT. The attached cells were
assayed for alkaline phosphatase activity by addition of 200 .mu.L
of 5 mM p-nitrophenylphosphate in 1 M diethanolamine, pH 10.4,
containing 0.1% (w/v) Triton X-100, incubation at 37.degree. C. for
30 min and measurement of absorbance at 405 nm on a Molecular
Devices ThermoMax plate reader.
[0117] The compounds of the present invention were assayed as set
forth above in order to evaluate their ability to induce expression
of alkaline phosphatase, an in vitro response specific to estrogen
agonists that has been shown to correlate with the in vivo
uterotrophic response of estrogen agonists in rats. Referring to
Table 1 below, results were expressed as the concentration of
various representative compounds of the present invention that
induced 50% of their maximal alkaline phosphatase activity
(E.sub.max), with this maximal activity expressed as a percentage
of the alkaline phosphatase activity induced by a saturating
concentation of estradiol. In additional studies it was shown that
all compounds whose E.sub.max was<20% functioned as antagonists
of estradiol at concentrations that mirrored their receptor binding
affinities.
1TABLE 1 Estrogen Agonist Activity Cmpd no. EC.sub.50 (nM).sup.b
E.sub.max (%).sup.c Estradiol 0.01 100 Tamoxifen 33 16.5 .+-. 0.6 1
2.3 11.9 .+-. 1.2 3 4.9 15.7 .+-. 1.8 4 20 18.8 .+-. 2.3 5 7.3 15.0
.+-. 3.0 9 58 3.8 .+-. 0.9 10 6.9 14.8 .+-. 2.4 11 11 14.0 .+-. 1.5
12 70 19.4 .+-. 2.0 13 4.6 16.5 .+-. 1.7 14 12 6.3 .+-. 1.2 15 8.6
8.9 .+-. 1.4 16 18 11.8 .+-. 1.9 21 6.9 18.8 .+-. 2.6 22 17 15.3
.+-. 2.4
[0118] Compound No. 1 was found to bind to the estrogen receptor
with approx. 10 fold higher affinity than tamoxifen which
translated to a lower EC.sub.50 in the Ishikawa cell functional
assay (see Table 1). In addition, Compound No. 1 possessed
significantly lower agonist activity (E.sub.max) than tamoxifen. A
series of amide analogs of Compound No. 1 were evaluated to
establish the structural requirements to lower the E.sub.50 and to
minimize E.sub.max in the Ishikawa cell functional assay. The data
showed that a wide range of structural diversity (lipophilicity,
steric bulk, H-bond donors and acceptors) was tolerated in this
region of the molecule, and only the bulky Compound No. 12 showed
reduced receptor affinity. Compound No. 1 showed the highest
affinity in the receptor binding assay and possessed the lowest
EC.sub.50 in the functional assay, however when E.sub.max data was
analyzed, Compound Nos. 9, 14 and 15 showed the lowest residual
agonist activity.
[0119] In order to evaluate the compounds set forth above for
in-vivo anti-uterotrophic activity, groups of five 21 day old
female SD rats (30-35 g) were weighed and the average weights
recorded for each treatment group as illustrated in FIG. 1. Stock
solutions (10.times.) of the triphenylethylene analogs in ethanol
were diluted with 0.5% methyl cellulose and 10 .mu.mol/kg was dosed
by gavage to the animals. Estradiol was dissolved in sesame oil and
100 nmol/kg dosed by subcutaneous injection. Animals were dosed for
3 days and sacrificed on day 4 by CO.sub.2 asphyxiation. The body
weights were obtained, uteri removed, blotted and weighed. Data is
expressed as uterine weight/body weight.+-.standard error. Solid
bars represent data from animals dosed with test compound alone.
Open bars represent data from animals dosed with test compounds 6h
prior to a dose of estradiol. Compounds 9 and 15 showed less
residual agonist activity than tamoxifen.
[0120] As an example of the functional profile of these compounds
in bone, Compound No. 9 was evaluated in 90 day old estrogen
deficient ovariectomized rats for their ability to inhibit loss of
bone mineral density. Ninety day old SD rats were divided into
groups of six. Three groups were surgically ovariectomized. Two
days post-ovariectomy, animals were dosed by gavage with either 10
.mu.mol/kg of Compound No. 9 in 0.5% methyl cellulose or vehicle
once a day for 28 days. One group of aminals was sham-operated, and
2 days post-ovariectomy dosed with vehicle once a day for 28 days.
At 0, 14 and 28 days, rats were anesthesized with isoflurane and
placed in the supine position with their spines parallel to the
long axis of the densitometer table. The lumbar spine was scanned
using the pelvic bones as a landmark. To scan the right tibia, the
leg was taped in position parallel to the long axis of the table
and scanned up to the junction with the femur. Analysis of the
lumbar spine was accomplished by dividing vertebra and
inter-vertebral spaces with normal analysis software and including
only target vertebra in the global region of interest. The right
tibia was analysed with subregional high resolution software,
focusing on the 3-5 mm distal from the growth plate previously
identified as a region of accelerated bone loss due to ovariectomy.
Data at 14 and 28 days did not differ significantly. Data at 28
days is shown in FIG. 2.
[0121] Referring to FIG. 2, an orally administered dose of 10
.mu.mol/kg of Compound No. 9 demonstrated full agonist activity,
maintaining BMD at the levels of the sham-operated rats for the
duration of the 28 day study. Biochemical data demonstrated that
the mechanism of action was through inhibition of bone resorption
consistent with their activity as estrogen agonists in bone. BMD
was measured by dual-energy X-ray absorptiometry using a Hologic
QDR-2000 bone densitometer using a regional high-resolution
software package with default scan length, width, line spacing and
point resolution of 2, 0.75, 0.01 and 0.005 in. respectively.
* * * * *